Excessive copper levels in the body led to an initial misdiagnosis of Wilson disease, a rare condition marked by copper buildup in the liver and…
News
FATTY LIVER DISEASE
NewsTherapy to silence SPTBN1 protein eases liver fat, scarring in mice
Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of two forms of fatty…
ALAGILLE SYNDROME
NewsNew study may explain milder liver scarring seen in Alagille syndrome
Alterations to the immune system may underlie the mild liver scarring, or fibrosis, that characterizes Alagille syndrome despite severe liver disease, according to a…
Fewer than half of reproductive-aged women with opioid use disorder in the U.S. undergo hepatitis C testing, with Black and Asian women less likely…
CHOLANGITIS
NewsFDA names volixibat, for itching due to PBC, a breakthrough therapy
The U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for the treatment of itching, or…
CHOLESTASIS
NewsNew ABCB11 mutation linked to PFIC2, hypothyroidism in boy
A new ABCB11 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 2 (PFIC2) in a boy who was also born with…
FATTY LIVER DISEASE
NewsSurvodutide wins breakthrough therapy for fatty liver disease
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…
BILIARY ATRESIA
NewsAmerican Liver Foundation launches free toolkit for children
The American Liver Foundation (ALF) has launched a toolkit — featuring a plush lion named Bili the Brave — to support children and families…
HEPATITIS
NewsAbbvie pulls 2 hepatitis treatments from EU market
Abbvie has decided to permanently discontinue the marketing of antiviral treatments Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) for adults with chronic hepatitis…
CHOLANGITIS
NewsIqirvo approved in UK for adults with PBC, problems with UDCA
U.K. regulators have approved Iqirvo (elafibranor) for adults with primary biliary cholangitis (PBC) who fail to respond to or cannot tolerate first-line…
Recent Posts
- For girl in Asia, limited access to genetic testing delayed an Alagille diagnosis
- FDA gives bepirovirsen priority review for chronic hepatitis B
- Starting disease marker levels may shape Iqirvo response in PBC
- The possibility for liver function to improve brings me hope
- New mouse model could help guide PFIC3 treatment research